Now Booking Free 30-minute strategy call For clinic founders and owners See if you qualify
Clinic owner highlighting a printed HHS peptide compounding policy at a bright office desk

HHS Peptide Compounding Policy: What Clinics Need to Know

November 11, 2026•7 min read

On October 28, 2026, not one peptide was added to the list of substances pharmacies may compound from. What the Department of Health and Human Services (HHS) did instead is narrower: it said it will not take enforcement action against certain compounders who meet ten conditions, for now. That difference decides what a clinic can say, buy and offer.

This guide from Altos Consulting Group (ACG) explains what HHS issued, which peptides and routes it covers, the ten conditions in plain words, and what the policy does not change. Our team has launched hundreds of clinics, and every peptide menu we plan starts from what is lawful today, the approach behind our peptide clinic consulting.

What the HHS Peptide Compounding Policy Is

The policy is titled "Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances." HHS filed it on October 28, 2026, and it was published on October 30, 2026 as FR Doc. 2026-22192 (Docket HHS-OASH-2026-0496), according to the Federal Register notice. Written comments were accepted for two weeks after publication, until November 13, 2026. As of November 13, 2026, HHS has not revised the policy.

Four facts about its status matter more than anything else in it:

  • It comes from HHS, not FDA. The HHS Office of the Secretary issued it.

  • It is a draft and an interim policy. The notice says it does not establish any rights and is not binding on HHS or the public.

  • It can change. HHS says it may revisit the policy in whole or in part if a safety signal or product quality issue arises, and a policy of enforcement discretion can be withdrawn without notice and comment, according to Arnold & Porter.

  • It is a bridge, not an answer. It applies while FDA decides through rulemaking whether to add these peptides to the 503A Bulks List. No proposed rule exists yet.

In the site's own words, it is a temporary HHS enforcement discretion policy (October 2026), not a listing or an approval.

Why the 503A Bulks List matters

Under section 503A, a pharmacy or physician may compound from a bulk substance only if it has a USP or NF monograph, is a component of an FDA-approved drug, or appears on the 503A Bulks List, according to FDA's page on bulk drug substances under section 503A. None of the six peptides in the policy meets any of those tests. The policy does not change that. It only describes when HHS does not intend to enforce it.

Pharmacist reviewing a certificate of analysis on a clipboard in a clean peptide compounding lab

What the Policy Covers

The policy covers state-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A. It does not name 503B outsourcing facilities.

It lists six peptides, each limited to a specific identity and route in the policy's appendix:

  • BPC-157 Acetate: subcutaneous, intramuscular, oral and topical forms

  • TB-500 Acetate: subcutaneous or intramuscular injection

  • Epitalon Acetate: subcutaneous or intramuscular injection, in intermittent courses

  • KPV Acetate: topical and oral forms

  • MOTS-c Acetate: subcutaneous or intramuscular injection

  • Semax (free base): intranasal use

A compounded product outside its listed identity or route falls outside the policy.

The Ten Conditions Compounders Must Meet

HHS's enforcement discretion applies only when every one of these conditions is met. In plain words, from the policy's appendix and cross-checked with Holland & Knight's summary:

1. A listed peptide only. The bulk substance is one of the six.

2. The listed identity and route. It matches the appendix, including its sequence and structure, and is compounded only for the routes listed.

3. A registered source with a valid certificate of analysis. The bulk substance comes from an FDA-registered facility, with a certificate of analysis whose test results meet FDA's criteria.

4. A registered, CGMP-compliant original manufacturer. The maker, not just a repacker or distributor, is FDA-registered and follows current good manufacturing practice, and its location appears on the certificate.

5. Adverse event reporting. Serious adverse events and product quality problems are reported to FDA's MedWatch and to the relevant states.

6. A required label statement. The label states that it is a compounded drug product and not for resale.

7. One listed ingredient per product. No combinations of listed peptides.

8. Oral bioavailability records. For oral forms, the compounder keeps documentation that the formulation is adequately absorbed in humans.

9. Only a cleared syringe. The only device packaged with the product is an FDA 510(k)-cleared syringe.

10. Every other federal rule. The product meets all other requirements of federal drug law, including sanitary conditions and a valid patient-specific prescription.

What the HHS Policy Does Not Change

This is the section to read slowly.

  • Compounded products are still not FDA-approved. The policy makes no finding about safety or effectiveness, and no compounded product may be presented as approved.

  • Research-use-only peptides are still never lawful to give a patient. The policy covers bulk substances from FDA-registered facilities with valid certificates of analysis. It does not reach material sold for research use only.

  • State law still applies in full. The policy addresses federal enforcement only. A state board of pharmacy or medicine can restrict, condition or prohibit compounding these peptides on its own.

  • It can be changed or withdrawn quickly. HHS can revise it if safety or quality concerns arise, and it ends for each peptide once FDA finishes rulemaking on that peptide, whichever way the rule goes.

Clinic owner and Medical Director reviewing a checklist on the HHS peptide compounding policy

What the Policy Means for a Clinic Owner

Here are the rules as they stand, and the questions to settle before anything changes on your menu.

  • Clinical decisions stay with the prescriber. Whether any compounded product is appropriate for a patient is a clinical decision, made by the prescriber at the Medical Director's discretion.

  • Ask your compounding pharmacy for its paperwork. Request the certificate of analysis for the bulk substance, the name and FDA registration of the original manufacturer, a copy of the label with the required statement, and how the pharmacy reports adverse events to MedWatch and the states. For how to vet a pharmacy partner, see our guide to peptide supplier access and compounding pharmacies.

  • Check your state first. Read your state board of pharmacy's and board of medicine's positions before anything is offered. A federal enforcement policy does not override a state restriction.

  • Keep marketing claims clean. No health or results claims, and no wording that presents a compounded product as FDA-approved.

For the wider compliance picture, including FDA's advisory committee votes and the Bulks List process, see our guide to peptide clinic compliance.

ACG's position

ACG builds a peptide menu on what is lawful today: sermorelin, FDA-approved products and compounded agents the pharmacy can document. The six peptides in the HHS policy stay on a tracked watch list, not on the menu, while this temporary policy settles. If rulemaking ever lists one of them, a clinic built on documented sourcing can add it quickly. Any question about one of them for a patient belongs to the Medical Director and healthcare counsel.

For founders, that position is part of how we help start a compliant peptide clinic. For practices already open, it shapes how we help add peptide therapy to an existing clinic. For the full opportunity and service stack, read our guide to the peptide therapy clinic business.

HHS Peptide Compounding Policy FAQs

Are the six peptides legal to compound now?

None of them is on the 503A Bulks List, and none is FDA-approved. The HHS policy says HHS does not intend to take federal enforcement action against covered compounders who meet all ten conditions. It is a temporary HHS enforcement discretion policy, not a listing or an approval, and state law can still restrict it.

Does the HHS policy cover 503B outsourcing facilities?

No. It covers state-licensed pharmacies, federal facilities and licensed physicians compounding under section 503A. It does not name 503B outsourcing facilities.

Does the policy override state law?

No. It addresses federal enforcement only. State boards of pharmacy and medicine can restrict, condition or prohibit compounding these peptides, so check your state before anything is offered.

How long will the policy last?

It applies until FDA addresses each peptide in a final rule on the 503A Bulks List, and HHS can revise or withdraw it sooner, including if a safety signal or quality problem arises. No proposed rule exists yet, so there is no date.

Can a clinic use research-use-only peptides?

No. Material sold for research use only is not a lawful source for a patient, and the policy does not change that. The policy depends on bulk substances from FDA-registered facilities with valid certificates of analysis. To plan a peptide program on lawful sourcing, book a free 30-minute strategy call.

This article is educational and is not legal or medical advice. Peptide compounding policy is changing quickly; confirm current status with healthcare counsel, your compounding pharmacy and your state boards. Status as of November 13, 2026.

Written by Nova, Senior Content Strategist at Altos Consulting Group.

Nova S.

Nova S.

Nova is Senior Content Strategist at Altos Consulting Group, building the content that helps founders open and grow regenerative health clinics.

Back to Blog
Built by operators. Our team has launched hundreds of clinics.